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AbstrAct
Introduction Adenocarcinoma in situ (AIS) of the 
uterine cervix is the precursor to invasive endocervical 
adenocarcinoma. An excisional biopsy such as a cold 
knife cone biopsy (CKC) should be performed to exclude 
invasive adenocarcinoma. Loop electrosurgical excision 
procedure (LEEP) is an alternative modality to CKC but is 
controversial in AIS. There is a perception that there is a 
greater likelihood of incomplete excision of AIS with LEEP 
because the depth of excised tissue tends to be smaller 
and the tissue margins may show thermal artefact which 
can interfere with pathology assessment. In the USA, 
guidelines recommend that any treatment modality can 
be used to excise AIS, provided that the specimen remains 
intact with interpretable margins. However, there are no 
high-quality studies comparing LEEP with CKC and well-
designed prospective studies are needed. If such a study 
were to show that LEEP was non-inferior to CKC for the 
outcomes of post-treatment persistence, recurrence and 
adenocarcinoma, LEEP could be recommended as an 
appropriate treatment option for AIS in selected patients. 
This would benefit women because, unlike CKC, LEEP does 
not require general anaesthesia and may be associated 
with reduced morbidity.
Methods and analysis The proposed exploratory study 
is a parallel group trial with an allocation ratio of 2:1 
in favour of the intervention (LEEP: CKC). Participants 
are women aged ≥18 to ≤45 years diagnosed with AIS 
on cervical screening and/or colposcopically directed 
biopsy in Australia and New Zealand, who are to receive 
excisional treatment in a tertiary level centre.
Ethics and dissemination Ethical approval for the study 
has been granted by the St John of God Healthcare Human 
Research Ethics Committee (reference number #1137). 
Results from the study will be presented at conferences 
and published in a peer-reviewed scientific journal.
registration ANZCTR registration number 
ACTRN12617000132347 https://www. anzctr. org. au/ Trial/ 
Registration/ TrialReview. aspx? id= 372173& isReview= true
IntroductIon
Adenocarcinoma in situ (AIS) of the uterine 
cervix is the precursor to, and may coexist 
with, invasive endocervical adenocarci-
noma.1 Current guidelines recommend that 
women in whom AIS is reported on screening 
cytology are referred to a gynaecologist with 
expertise in the colposcopic evaluation of 
suspected malignancies or a gynaecologic 
oncologist, and if invasive disease is not iden-
tified at colposcopy, a cold  knife cone biopsy 
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Protocol
strengths and limitations of the study
 ► Strengths of this pilot study include its prospective, 
randomised design, allocation concealment and 
strategies to minimise surgical performance bias. 
Should the pilot study demonstrate safety and 
feasibility, potential limitations of a subsequent 
phase III study include those pertaining to non-
inferiority trials which lack a placebo group, can only 
provide an indirect assessment of the efficacy of the 
treatment compared with an existing standard and 
where the choice of non-inferiority margin can be 
subjective.
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(CKC) should be performed to exclude invasive adeno-
carcinoma.2 3
The role of alternative excision modalities to CKC in 
the investigation and management of AIS has been the 
subject of extensive debate. Single-specimen excision 
biopsies with minimal thermal damage or disruption 
of resection margins are essential for accurate histo-
pathological assessment. A comprehensive review of the 
Australian 2005 National Cervical Screening Programme 
(NCSP) guidelines2 has recommended that ‘cold-knife 
cone biopsy should be considered the "gold standard" 
for the diagnostic assessment of glandular lesions. 
However, a diathermy excisional procedure may be 
appropriate in some circumstances and could provide 
an appropriate surgical specimen when performed by 
a gynaecologist with appropriate training, experience 
and expertise’.4 There is a perception that there is a 
greater likelihood of incomplete excision with loop 
electrosurgical excision procedure (LEEP) because 
the depth of excised tissue and the overall dimensions 
of the specimen tend to be smaller in comparison to 
CKC. It is also argued that the tissue margins in a LEEP 
biopsy may show significant thermal artefact, which can 
interfere with the pathological assessment of biopsy 
margins.5 6 Some studies have shown a greater risk of a 
positive endocervical margin with LEEP but these have 
included cases in which AIS was not suspected prior to 
the excisional procedure.7–9 However, current Amer-
ican Society for Colposcopy and Cervical Pathology 
consensus guidelines recommend that any treatment 
modality can be used for diagnostic excision, provided 
that the specimen remains intact with interpretable 
margins and that there is no fragmentation, including 
‘top-hat’ serial endocervical excisions.3
Conservative treatment of women with AIS by CKC or 
LEEP is also controversial because AIS may co-exist with 
cervical adenocarcinoma10 and hence total hysterectomy 
has been regarded as definitive management.3 However, 
CKC and LEEP present fertility-preserving alternatives to 
hysterectomy in women of reproductive age in whom AIS 
is prevalent.11 12
Positive or close histopathological margins have been 
associated with an increased risk of AIS persistence and 
recurrence.13 A 2014 systematic review14 reported higher 
rates of incomplete excision with LEEP (51%) than 
with CKC (30%) or laser cone (28%) using pooled data 
and reported rates of recurrence of AIS ranging from 
9% to 29% after LEEP and from 6% to 11% after CKC. 
This review concluded that LEEP had acceptable safety 
and was comparable to CKC when negative margins 
were achieved, and is associated with better obstetric 
outcomes.14 Furthermore, recent evidence suggests that 
CKC and LEEP are associated with similar rates of posi-
tive margins and recurrent AIS.15 Advantages of LEEP 
compared with CKC include the ability to perform the 
procedure under local anaesthesia in an outpatient 
setting and lower morbidity, including adverse obstetric 
outcomes.16 17
There are no prospective randomised studies of AIS 
treatment to inform clinical practice. More recent retro-
spective studies have found similar recurrence and 
persistence rates for LEEP and CKC.18 19 The absence of 
prospective randomised studies has recently been high-
lighted by Cancer Council Australia’s working party draft 
clinical management guidelines for the prevention of 
cervical cancer.4 There is a clear need for prospective 
randomised clinical trials to determine whether LEEP 
is associated with similar histopathological and clinical 
outcomes when compared with CKC in the investigation 
and management of cervical AIS.
The Cancer Council Australia Cervical Cancer Screening 
Guidelines Working Party argued that 'Well-designed 
prospective research studies are needed to compare the 
use of cold knife cone biopsy with diathermy loop excision 
(LEEP or LLETZ) in the diagnosis and treatment of AIS. If 
such a study were to show that loop excision was non-inferior 
to cold-knife cone biopsy for the outcomes of post-treat-
ment persistence and recurrence, and adenocarcinoma, 
loop excision could be recommended as an appropriate 
treatment option for AIS in selected patients. This would 
benefit women because, unlike cold-knife cone procedures, 
loop excision does not require hospital admission and 
general anaesthesia. Studies evaluating endocervical curet-
tage would provide useful evidence to determine its role in 
clinical practice. Long-term data from the National Cervical 
Screening Program should be analysed to determine the 
minimal effective surveillance period for women under-
going annual Test of Cure for post-treatment AIS before 
returning to routine 5-yearly screening’.4
The aim of the proposed pilot study is to demonstrate 
the feasibility and safety of LEEP versus CKC for the 
treatment of cervical AIS prior to conducting a phase III 
prospective multicentre randomised non-inferiority trial.
The specific objectives of the proposed phase I study 
are
1. to compare LEEP with CKC in terms of margin status 
and specimen dimensions
2. to compare rates of early complications at 6 weeks, 
for example, pain, infection, primary and secondary 
haemorrhage, readmission to hospital, return to the 
operating theatre after the two treatment modalities
3. to assess patient satisfaction following LEEP and CKC
4. to determine the costs of treatment.
If feasibility and safety are demonstrated, the objective 
of the subsequent phase III trial would be to determine 
if the treatment of cervical AIS by LEEP is non-inferior 
to CKC in terms of disease persistence at 12 months and 
recurrence at 5 years in women managed conservatively, 
when treatment is performed in tertiary level dysplasia 
and gynaecologic oncology centres.
MEthods And AnAlysIs
The protocol conforms to the SPIRIT (Standard Protocol 
Items for Randomised Trials) statement.
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trial design
The proposed exploratory study is a parallel group trial 
with an allocation ratio of 2:1 in favour of the interven-
tion (LEEP: CKC).
study setting
Academic tertiary level hospitals in Australia and New 
Zealand.
Study sites are listed in the ANZCTR registration 
number ACTRN12617000132347.
Web address: http://www. ANZCTR. org. au/ 
ACTRN12617000132347. aspx
Eligibility criteria
Women aged ≥18 to ≤45 years diagnosed with AIS on 
cervical screening and/or colposcopically directed biopsy 
in Australia and New Zealand, who are to receive exci-
sional treatment in a tertiary level centre.
Inclusion criteria
 ► Aged between ≥18 and 45 years of age at time of study 
enrolment
 ► Documentation of AIS on cervical cytology and/or 
cervical biopsy test results
 ► Lesion amenable to single-pass excision (serial en-
docervical excisions including ‘top-hat’ will not be 
permitted in accordance with American Society for 
Colposcopy and Cervical Pathology Recommenda-
tions)7
 ► Proficient in English.
Exclusion criteria
 ► High-grade cervical abnormality prior to current AIS 
diagnosis
 ► Previous excisional or ablative treatment (LEEP, CKC, 
Fisher cone biopsy, laser cone, laser ablation, radical 
diathermy)
 ► Previous history of cervical cancer treated by radia-
tion or chemoradiation
 ► Cytology suspicious of invasion
 ► Clinical/colposcopic suspicion of invasion
 ► Presence of a concurrent gynaecological cancer
 ► Patients unable to comply with follow-up evaluations
 ► Immunosuppression
 ► Pregnancy
 ► Lesion considered unsuitable for single-pass excision 
by treating specialist.
Interventions
Eligible participants will be randomised to undergo 
either LEEP or CKC. LEEP is the standard procedure 
performed for the more common high-grade squamous 
cervical dysplasia and the technique is described in 
detail in online supplementary appendix A. In Australia, 
CKC has been the preferred technique to excise cervical 
AIS and the technique is outlined in online supplemen-
tary appendix A. The interventions will be administered 
within the usual clinical time frames as per local prac-
tice.
Patient management will follow the National Health 
and Medical Research Council’s 2005 Screening to 
prevent cervical cancer: guidelines for the management of 
asymptomatic women with screen-detected abnormalities 
and the revised 2016 guidelines. Participants randomised 
to the LEEP arm of the study will have their procedure 
performed either under local or general anaesthesia in 
an outpatient setting or operating theatre at the discre-
tion of the treating specialist as per local routine practice. 
All participants will undergo endocervical curettage at 
the time of their LEEP or CKC.
Following treatment, all patients will undergo the ‘Test 
of Cure’ management pathway:
1. colposcopy and cervical cytology at 6 months’ 
postexcisional treatment
2. cervical cytology and oncogenic human papilloma 
virus (HPV) typing at 12 months’ post-treatment and 
then annually in accordance with the revised 2017 
NCSP guidelines.4
Methods for protecting against sources of bias
A potential issue in surgical trials is performance bias. The 
study setting will be tertiary level dysplasia/gynaecologic 
oncology units and only the named study investigators 
will be performing the excisional procedures which will 
mitigate this bias to some extent. All clinical investigators 
are highly experienced providers and are certified under 
the Colposcopy Quality Improvement Programme in 
accordance with the requirements of the Royal Australia 
and New Zealand College of Obstetrics and Gynaecology. 
The requirement for a single-pass specimen will also limit 
surgical performance bias.
strategies to improve adherence to intervention protocols and 
any procedures for monitoring adherence
It is anticipated that participants will attend for treat-
ment and those who do not attend will be recalled as 
per routine clinical practice. Participants will be encour-
aged to complete the patient satisfaction questionnaire 
at 6 weeks’ post-treatment by a phone call and/or email 
from the site trial co-ordinators.
outcomes
Primary outcomes: Histopathological margin status and 
status of the excised specimen (single specimen or more 
than one piece).
Rationale: Margin status has consistently been shown 
to predict persistence and recurrence of cervical AIS.13 
Disruption to the excision specimen can make orienta-
tion and interpretation of tissue margins impossible. If 
there are significantly more LEEP specimens with positive 
margins compared with those excised by CKC, or if there 
are a greater number of specimens excised in more than 
one piece compared with CKC, then it may not be appro-
priate to conduct a larger phase III study.
Key secondary outcomes: Frequency of early complica-
tions (pain, infection, primary and delayed haemorrhage, 
readmission to hospital, return to the operating theatre), 
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Figure 1 Consolidated standards of reporting trials (CONSORT) flow diagram of EXCISE study. CKC, cold knife cone biopsy; 
LEEP, loop electrosurgical excision procedure.
patient satisfaction at 6 weeks’ postprocedure and costs of 
treatment.
Rationale: Retrospective studies have suggested that 
LEEP is associated with fewer early complications.16 17 
Although the proposed study is underpowered to detect 
differences in these outcomes, the purpose of their inclu-
sion is to determine the feasibility of data collection.
Participant timelines
Figure 1 shows a consolidated standards of reporting 
trials (CONSORT) flow diagram of the EXcisional 
treatment Comparison for  In Situ Endocervical adeno-
carcinoma (EXCISE) study. The schedule of enrolment, 
interventions and assessments is presented in figure 2. 
Following randomisation, participants will undergo the 
treatment to which they are allocated (LEEP or CKC). 
LEEP and CKC are usually day-case procedures. Partic-
ipants will have one follow-up visit with a local study 
co-ordinator at 6 weeks’ postprocedure. This visit may be 
conducted face to face or via telephone and will involve 
collection of information regarding complications post-
procedure, return to hospital, general practitioner (GP) 
visits and a request to complete and return the patient 
satisfaction questionnaire. 
We are aiming to recruit 35–40 participants for the 
proposed phase I study. This sample size was determined 
on a pragmatic basis (five patients recruited at each of 
seven participating sites).
sample size
The sample size for the pilot study is pragmatic. The 
sample size for the potential subsequent phase III study 
was estimated using a two-group test of non-inferiority 
of proportions, where the primary end point is the AIS 
recurrence rate at 5 years and the comparison will be 
between CKC and LEEP, based on a one-sided test for 
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Figure 2 Schedule of enrolment, interventions and assessments. AIS, adenocarcinoma in situ; BMI, body mass index; CKC, 
cold knife cone biopsy; HPV, human papilloma virus; LEEP, loop electrosurgical excision procedure; STI, sexually transmitted 
infection.
non-inferiority. If we assume for patients in the standard 
treatment arm an 8% rate of AIS recurrence at 5 years, 
and a 5% non-inferiority margin (so an upper 95% confi-
dence rate of AIS recurrence of 13% is still within the 
non-inferiority margin), the total sample size needed 
is 730 (365 per group). Assuming a 10% drop-out rate, 
a total sample size of 810 participants (405 per group) 
would need to be randomised. The one-sided type I error 
is set at 5% with 80% power. Kaplan-Meier and log-rank 
tests will be used to test for non-inferiority at median 
follow-up of 5 years (with patient recruitment between 
4 and 5 years, assuming 160–200 patients are successfully 
randomised per annum). Proportional hazard models 
will be used to test for differences between the two treat-
ment groups controlling for confounding variables. All 
statistical analysis will be carried out as per CONSORT 
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recommendations for non-inferiority randomised 
controlled trials using intent-to-treat as well as per-pro-
tocol populations.
recruitment: strategies for achieving adequate participant 
enrolment to reach target sample size
Several of the investigators are the clinical leads of their 
local dysplasia units and triage patient referrals to their 
centres. They will be ideally placed to identify potential 
eligible participants. The investigators believe that it is 
feasible to recruit the number of participants needed for 
this phase I study based on the local incidence of cervical 
AIS and enrolment rates in previous research studies.
Assignment of interventions
Allocation: Participants will be randomised to undergo 
LEEP or CKC (2:1 ratio).
Generation of the allocation sequence will be by 
computer-generated random numbers. The allocation 
sequence will be implemented by central telephone 
(interactive voice response system) and will be gener-
ated by the National Health and Medical Research 
Council (NHMRC) Clinical Trials Centre, University of 
Sydney.
Participants will be enrolled by the treating specialist 
who will be one of the named investigators. Following 
randomisation, participants will be assigned to LEEP or 
CKC by a study co-ordinator at each site.
blinding
All study investigators and participants will not be blinded 
to the intervention.
data collection, management and analysis
A case report form (CRF) will be used to record data for 
each participant. The primary outcomes will be assessed 
as part of routine clinical care by the reporting consul-
tant anatomical pathologists at each site. All participating 
sites will be required to complete synoptic/standardised 
histopathology reports for each study participant. All spec-
imens will undergo centralised pathology review at Royal 
Prince Alfred Hospital, Camperdown, New South Wales, 
Australia, by Dr Lyndal Anderson, Consultant Pathologist 
and Study Investigator. Data regarding early complica-
tions will be obtained via patient medical records and at 
patient follow-up visits and recorded on the CRF by the 
site study co-ordinator. Patient satisfaction will be assessed 
by using those aspects of the European Organization for 
Research and Treatment of Cancer in-patient satisfaction 
(EORTC IN-PATSAT32) which are pertinent to outpa-
tient care, as well as additional questions on the ease of 
making appointments, clinic accessibility and waiting 
times.20 21 The intervention is a surgical procedure so 
once performed it will not be possible for participants to 
deviate from the intervention protocol. Should a partic-
ipant withdraw from the study postintervention then it 
may not be possible to obtain data regarding secondary 
outcomes (early complications and patient satisfaction).
Data will only be collected with the signed permis-
sion of the participant. All questionnaires/data CRFs 
will be given a unique identity number (de-identified 
data) and will not include information that would allow 
identification of the participant. Unique patient identifi-
cation number will be generated by the interactive voice 
response system (IVRS) and identified patient data will 
only be available to the principal investigators at each 
participating institution. Only de-identified clinical infor-
mation will be used for statistical analysis and reporting.
The original study participant CRFs will be stored 
securely by the relevant study site investigators. Copies 
of the completed CRFs accompanied with de-identified 
supporting source documents will be scanned by the 
study site researchers, saved in a PDF format and these 
version files will be emailed to the lead site for data entry.
The study standard operating procedures (SOP)will 
be used to ensure the collection of accurate, consistent, 
complete and reliable data. In addition, prior to the 
study initiation at each site, an investigator meeting and 
training session will be held via teleconference to prepare 
both the investigators and other trial staff involved and to 
standardise performance.
Safety reporting will be conducted according to trial 
specific procedures. Data management will be performed 
by the lead site. Accurate and reliable data collection 
will be assured by 100% verification and crosscheck of 
CRFs against the investigator’s records by the St John of 
God (SJOG) Gynaecological Cancer Research Group.
All data will be stored in locked offices, password-pro-
tected computer files and password-protected database, 
accessible only by site staff. A FileMaker Pro database 
will be used for the data management, and data from 
the CRFs will be entered into the database by the SJOG 
Gynaecological Cancer Research Group.
safety monitoring
An independent medical monitor (IMM) will undertake 
ongoing safety monitoring throughout the trials duration 
assessing serious adverse events (SAE) and suspected, 
unexpected adverse reactions (SUSARs) reported by 
research sites to the Trial Steering Committee (TSC). 
The IMM will provide recommendations whether the 
study should continue as planned or that changes should 
be made to the protocol to improve safety. If matters of 
major safety are identified, for example, a higher than 
expected SUSARs/SAEs being reported, the IMM can 
recommend that the study be postponed until matters 
are clarified and resolved. Otherwise, if study participant 
safety is compromised, the study must be terminated.
data monitoring
A systematic, prioritised risk-based monitoring schedule 
will be implemented by the study sponsor in accordance 
with International Conference on Harmonisation Good 
Clinical Practice (ICH GCP) (5.18 Monitoring) guide-
lines. It will encompass both on-site monitoring and 
centralised remote monitoring modalities. On-site 
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monitoring will verify that study participants have given 
their consent to participate voluntarily, have been fully 
informed of the research trial and that their rights, safety 
and well-being are assured. Additionally, the monitoring 
will verify that the data collected are accurate, complete 
and verifiable from source documents and that the site 
research personnel are conducting the trial in accordance 
with the Human Research Ethics Committee (HREC) 
approved study protocol and its ‘conditions of approval’.
Centralised monitoring will complement and reduce 
on-site monitoring whereby reliable data and potentially 
unreliable data can be distinguished, that is, omissions, 
inconsistencies, incongruous or anomalous data entries 
will be identified and queries can be clarified and where 
applicable, corrected and resolved in a timely manner 
with the relevant study sites in accordance with GCP 
guidelines.
harms
The investigator is responsible for reporting all AEs and 
SAEs that are observed during the study, regardless of 
their relationship to treatment or their clinical signifi-
cance. All AEs and SAEs that occur after surgery during 
the study must be recorded in the patient’s chart and the 
CRFs and followed to a satisfactory resolution or until the 
local Investigator deems the patient to be stable or the 
AE/SAE to have resolved. The description of the AE/SAE 
will include the onset date, duration, date of resolution, 
severity, seriousness, aetiology and the likelihood of rela-
tionship of the AE to study treatment. Severity of AEs will 
be graded using the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.0 
(CTC- AE v4.0).
If an AE occurs which is not contained in the CTC-AE 
v4.0, the following five-point scale will be used:
1. mild: discomfort noticed but no disruption of normal 
daily activity
2. moderate: discomfort sufficient to reduce or affect 
daily activity
3. severe: inability to work or perform normal daily 
activity
4. life threatening: represents an immediate threat to 
life
5. death.
Any AE considered serious by the local Investigator 
or which meets the previous criteria must be reported 
to the TSC. A CRF and SOP for SAE reporting will be 
provided by the lead site. If the patient is hospitalised 
because of, or during, an SAE, then a copy of the hospital 
discharge summary and any other reports/results should 
be emailed to the lead site (SJOG Subiaco) as soon as they 
are available.
Once an investigator becomes aware that an SAE has 
occurred in a study participant, they will immediately 
notify the lead site via email. The SAE form must be 
completed by site personnel as thoroughly as possible with 
all available details of the event, signed by the investigator 
(or appropriately qualified designee) and emailed to the 
lead site within 24 hours of first becoming aware of the 
event. The investigator will always provide an assessment 
of causality at the time of the initial report. 
All sites are required to submit locally occurring SAEs 
to their reviewing ethics committee or site governance 
office within 24 hours of first notification of SAE occur-
rence or according to local HREC policy.
At every study visit, patients will be asked a standard 
non-leading question to obtain any medically related 
changes in their well-being. They will also be asked if 
they have been hospitalised, had any accidents, used any 
new medications or changed concomitant medication 
regimens (prescription, over-the-counter medications 
and herbal supplements). In addition to patient or inves-
tigator observations, AEs will be documented from any 
data collected (eg, laboratory values, physical examina-
tion findings), or other documents that are relevant to 
patient safety.
The investigator’s assessment of an AE's relationship to 
treatment is part of the documentation process, but it is 
not a factor in determining what is or is not reported in 
the study. If there is any doubt as to whether a clinical 
observation is an AE, the event should be reported.
All AEs and SAEs will be followed until resolution, 
until the condition stabilises, until the event is otherwise 
explained, until the participant is lost to follow-up or up 
to close out visit.
Once resolved, the appropriate AE/SAE CRF page(s) 
will be updated. The investigator will ensure that follow-up 
includes any supplemental investigations as may be indi-
cated to elucidate the nature and/or causality of the AE 
or SAE. This may include additional laboratory tests or 
investigations, histopathological examinations or consul-
tation with other healthcare professionals.
New or updated information for SAEs will be recorded 
on the originally completed SAE form, with all changes 
signed and dated by the investigator or designee. The 
updated SAE form should be resent to the SJOG Gynae-
cological Cancer Research Group.
AudItIng
Participating sites will be audited at least once during the 
pilot phase by a study monitor who is an employee of the 
sponsor but independent of the investigators.
EthIcs And dIssEMInAtIon
Ethical approval for the study has been granted by the 
St John of God Healthcare Human Research Ethics 
Committee (reference number #1137). Important 
protocol modifications will be submitted to the St John 
of God Subiaco Hospital HREC as requests to amend 
the approved study protocol. Informed consent will be 
obtained by the participant’s treating specialist. Only the 
investigators, data manager and trial co-ordinator at St 
John of God Subiaco Hospital will have access to the final 
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trial dataset. Participants will undergo post-trial care in 
accordance with NHMRC guidelines for the follow-up 
of women after treatment for cervical AIS. There are no 
provisions for those who suffer harm from trial partici-
pation as any harm would be regarded as having arisen 
because of routine treatment and not specifically due to 
trial participation.
The investigators and sponsor do not intend to commu-
nicate results directly to participants. Results from the 
study will be presented at national and international 
conferences and published in a peer-reviewed scientific 
journal. The authorship guidelines largely follow the rules 
established by the International Committee of Medical 
Journal Editors.22 The investigators do not intend to use 
professional writers.
dIscussIon
In contrast to cervical squamous dysplasia, the incidence 
of AIS is increasing in relative and absolute terms. There 
is a clear need for prospective randomised clinical trials to 
determine whether LEEP is associated with similar histo-
pathological and clinical outcomes when compared with 
CKC in the investigation and management of cervical 
AIS. This is the first prospective randomised study to 
investigate this clinical question. Limitations of the pilot 
study are its relatively short follow-up period (6 weeks) 
and small sample size, which are pragmatic. The objec-
tive of the pilot study is to demonstrate the feasibility 
and safety of the intervention as defined by pathological 
margin status, and hence long-term outcomes of interest 
including rates of cervical AIS recurrence and obstetric 
complications will be endpoints in a subsequent phase 
III trial. Limitations of a phase III study include those 
of non-inferiority trials such as defining the acceptable 
margin of AEs that would render the interventional treat-
ment inferior, lack of a placebo group and allowing only 
an indirect assessment of the efficacy of the intervention 
compared with an accepted standard.
Strengths of the study include its randomised design 
and attempts to minimise surgical performance bias. 
If LEEP was found to be non-inferior to CKC for the 
outcomes of post-treatment persistence and recurrence, 
and adenocarcinoma, it could be recommended as an 
appropriate treatment option for AIS in selected patients. 
This would benefit women because, unlike cold knife 
cone procedures, loop excision does not require hospital 
admission and general anaesthesia.
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